Eupraxia Pharmaceuticals reports Q2 results

• Eupraxia Pharmaceuticals press release (OTCPK:EPRXF): Q2 net loss of $6.3 million.
• The Company had a cash and short-term investments balance of $35.5 million as at June 30, 2022. Management believes it has sufficient resources to fund the Company through to the fourth quarter of 2023.